



Date	Time	Track	Presentation Title	Speaker
13-Feb	06:00 - 07:00 AM	Digitization, Digitalization & Digital Transformation	Amplifying Human Ingenuity with Intelligent Technology	Claudio Mirti Principal Solution Specialist, Data & AI, Microsoft
13-Feb	07:30 - 08:30 AM	Non-Traditional In Vivo & In Vitro Models	Keynote Presentation: Modernizing Drug Development Through Digital Transformation and Non-Traditional Models	Szczepan Baran, VMD, MS Head of Emerging Technologies, LAS, Novartis
13-Feb	09:00 - 10:00 AM	Digitization, Digitalization & Digital Transformation	Making Data Fly in Formation	Chuck Donnelly CEO & Founder, RockStep Solutions Julie Morrison Vice President/Principal, RockStep Solutions
13-Feb	10:30 - 11:30 AM	Non-Traditional In Vivo & In Vitro Models	Accurate Clinical Concentration-Response Predictions for Cardiac Arrhythmias Using a Population-Based in Vitro/In Silico Model	Weihsueh Chiu, PhD Professor, Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University
13-Feb	10:30 - 11:30 AM	Digitization, Digitalization & Digital Transformation	Qualitative, Biased, Personal and Speculative Remarks on Digitization, Digitalization & Digital Transformation	Sean Maguire, VMD, MS, DACLAM GSK Associate Fellow, Comparative & Translational Sciences Veterinarian, GlaxoSmithKline
13-Feb	12:00 - 01:00 PM	Digitization, Digitalization & Digital Transformation	Automatic Detection and Classification of Behaviour in Laboratory Animals	Patrick Sweeney, PhD Founder & Chief Operating Officer, Naason Science, Inc.
13-Feb	01:30 - 02:30 PM	Digitization, Digitalization & Digital Transformation	Precision Medicine for Mice: Digital Biomarkers Transforming Drug Discovery	Laura Schaevitz, PhD Chief Scientific Officer, Vium

14-Feb	06:00 - 07:00 AM	Digitization, Digitalization & Digital Transformation	Connected Data: Linking Pre-Clinical Data to Commercial Outcomes for Patients Today	Wu Wu Engagement Manager, Ernst and Young
14-Feb	06:00 - 07:00 AM	Non-Traditional In Vivo & In Vitro Models	The NIH Microphysiological Systems Program	Danilo Tagle, PhD, M.S. Associate Director for Special Initiatives Office of the Director National Center for Advancing Translational Sciences, National Institutes of Health
14-Feb	07:30 - 08:30 AM	Non-Traditional In Vivo & In Vitro Models	Keynote Presentation: A Comparative Approach to Oncology Drug Development: Integrating Canine Models	Amy LeBlanc, DVM DACVIM Director, Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
14-Feb	09:00 - 10:00 AM	Digitization, Digitalization & Digital Transformation	General Informatics Strategy for Specific Scientific Data (From Collection to Insight)	Yohann Potier, PhD Technical Associate Director, Novartis Institutes for BioMedical Research
14-Feb	09:00 - 10:00 AM	Digitization, Digitalization & Digital Transformation	General Informatics Strategy for Specific Scientific Data (From Collection to Insight)	Yohann Potier, PhD Technical Associate Director, Novartis Institutes for BioMedical Research
14-Feb	09:00 - 10:00 AM	Non-Traditional In Vivo & In Vitro Models	Tissue Chips: Building Confidence Through Independent Experimental Testing	Ivan Rusyn, PhD Professor, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University
14-Feb	10:30 - 11:30 AM	Non-Traditional In Vivo & In Vitro Models	Integrating In Vitro Microtissues and In Vivo endpoints in Drug Discovery & Development	Matthew Wagoner, PhD Associate Director of Mechanistic and Investigative Toxicology, Takeda Pharmaceuticals
14-Feb	12:00 - 01:00 PM	Non-Traditional In Vivo & In Vitro Models	Application of Micro-Physiological Systems for Respiratory Drug Discovery: Opportunities and Challenges	David Rowlands, PhD Senior Investigator and Group Leader, Respiratory Biology, Novartis Institutes for BioMedical Research
14-Feb	01:30 - 02:30 PM	Non-Traditional In Vivo & In Vitro Models	Organs On a Chip: A Revolution in Drug Development?	Gorm Yoder, PhD Scientific Director, Analytical Development, Small Molecule Pharmaceutical Development, The Janssen Pharmaceutical Companies of Johnson & Johnson